Drug Type Monoclonal antibody |
Synonyms SHR 1314, SHR-1314, SHR1314 |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | NDA/BLA | CN | 08 Feb 2024 | |
Plaque psoriasis | NDA/BLA | CN | - | |
Graves Ophthalmopathy | Phase 2 | - | 13 Jun 2022 | |
Arthritis, Psoriatic | Phase 2 | CN | 22 Oct 2021 | |
Lupus Nephritis | Phase 2 | CN | 08 Jun 2021 | |
Chronic large plaque psoriasis | Phase 1 | CN | 13 Aug 2018 | |
Axial Spondyloarthritis | Phase 1 | CN | 19 Apr 2018 | |
Psoriasis | Phase 1 | AU | 22 Aug 2016 |
Phase 2/3 | 548 | gngbewinqg(mpgckfaqiy) = 与安慰剂相比,SHR-1314对活动性强直性脊柱炎具有统计学显著性和临床意义的改善。 fffgtyipye (paudstfgpj ) Met View more | Positive | 18 Feb 2024 | |||
安慰剂 | |||||||
Phase 3 | 690 | snhlmzlbdk(dnltkkkgqf) = jieaebpjcg ofaagvhsna (uqsbdpldac, 72.7 - 80.5) View more | Positive | 11 Oct 2023 | |||
Placebo | snhlmzlbdk(dnltkkkgqf) = qaordmymjb ofaagvhsna (uqsbdpldac, 0.2 - 3.1) View more | ||||||
Phase 2 | 187 | jsiptdhkgp(eelvijrgzb) = wknfcgpxpz ysueinlflu (ymbebsifrh ) | Positive | 10 Jan 2022 | |||
jsiptdhkgp(eelvijrgzb) = jsrexjzexs ysueinlflu (ymbebsifrh ) |